OXGN Stock - OXiGENE, Inc.

OXGN Stock Chart

OXGN Profile

OXGN (OXiGENE, Inc.) was a clinical-stage biopharmaceutical company that focused on developing novel drugs for the treatment of cancer. The company's lead product candidate was Zybrestat, which was designed to treat solid tumors by disrupting the blood vessels that supply the tumors with nutrients.

In March 2017, OXiGENE merged with Mateon Therapeutics to create Mateon Therapeutics Inc. The merged company focused on the development of therapeutics to treat oncology, immuno-oncology, and infectious diseases.